(Q57159199)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

title

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

Yousef Zakharia

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

author name string

Mark G Manfredi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

George C Prendergast

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

language of work or name

English

0 references

publication date

10 September 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

Seminars in Immunopathology

22 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

page(s)

41-48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

Induction of pulmonary indoleamine 2,3-dioxygenase by interferon

22 April 2020

cites work

1 reference

12 December 2020

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

1 reference

12 December 2020

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

1 reference

12 December 2020

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

1 reference

12 December 2020

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

1 reference

12 December 2020

Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice

1 reference

12 December 2020

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan

1 reference

12 December 2020

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase

1 reference

12 December 2020

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism

1 reference

12 December 2020

Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection

1 reference

12 December 2020

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

1 reference

12 December 2020

Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target

1 reference

12 December 2020

Infectious tolerance via the consumption of essential amino acids and mTOR signaling

1 reference

12 December 2020

Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate

1 reference

12 December 2020

Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation.

1 reference

12 December 2020

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

1 reference

12 December 2020

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

1 reference

12 December 2020

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

1 reference

12 December 2020

Cancer: Why tumours eat tryptophan

1 reference

12 December 2020

IDO is a nodal pathogenic driver of lung cancer and metastasis development

1 reference

12 December 2020

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

1 reference

12 December 2020

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

1 reference

12 December 2020

Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target

1 reference

12 December 2020

Small molecule modulators of eukaryotic initiation factor 2α kinases, the key regulators of protein synthesis.

1 reference

12 December 2020

Inhibition of indoleamine 2,3-dioxygenase in mixed lymphocyte reaction affects glucose influx and enzymes involved in aerobic glycolysis and glutaminolysis in alloreactive T-cells.

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

1 reference

12 December 2020

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma

1 reference

12 December 2020

Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues.

1 reference

12 December 2020

IDO2 in Immunomodulation and Autoimmune Disease

1 reference

12 December 2020

A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.

1 reference

12 December 2020

Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia.

1 reference

12 December 2020

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

1 reference

12 December 2020

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

1 reference

12 December 2020

Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.

1 reference

12 December 2020

IDO1 is an Integral Mediator of Inflammatory Neovascularization.

1 reference

12 December 2020

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

1 reference

12 December 2020

In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.

1 reference

12 December 2020

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

1 reference

12 December 2020

Epacadostat Shows Value in Two SCCHN Trials

1 reference

12 December 2020

IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.

1 reference

12 December 2020

Discovery of IDO1 Inhibitors: From Bench to Bedside

1 reference

12 December 2020

Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities

1 reference

12 December 2020

Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment

1 reference

12 December 2020

Regulation of the Immune Response by the Aryl Hydrocarbon Receptor.

1 reference

12 December 2020

Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.

1 reference

12 December 2020

Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.

1 reference

12 December 2020

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss of Function Polymorphisms and Indoleamine-2,3-Dioxygenase-2.

1 reference

12 December 2020

IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.

1 reference

12 December 2020

Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme

1 reference

12 December 2020

Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer

1 reference

12 December 2020

Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers

1 reference

12 December 2020

10.1007/S00281-018-0702-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30203227%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

1 reference